Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CXCR5 | P32302 | 4/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23223983 | 0.89 | EPHX1 (0.38) | EPHX1EPHX2RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL18918513 | 0.83 | CHRM3 (0.37) | EPHX2 | |
| SCHEMBL18271811 | 0.74 | EPHX1 (0.46) | EPHX1RAB9ASMN1; SMN2NPC1USP2 | |
| SCHEMBL23223708 | 0.70 | ADRB2 (0.42) | RAB9ASMN1; SMN2NPC1USP2L3MBTL1 | |
| SCHEMBL18918551 | 0.69 | EPHX1 (0.43) | EPHX1RAB9ASMN1; SMN2NPC1USP2 | |
| SCHEMBL23198044 | 0.69 | ADRB2 (0.62) | — | |
| SCHEMBL560070 | 0.67 | HTT (0.55) | EPHX1KMT2AHPGD | |
| SCHEMBL29798859 | 0.65 | NPC1 (0.58) | EPHX1RAB9ASMN1; SMN2NPC1L3MBTL1 | |
| SCHEMBL18946463 | 0.64 | EPHX1 (0.40) | EPHX1RAB9ASMN1; SMN2NPC1NAMPT | |
| SCHEMBL23223706 | 0.64 | GAA (0.39) | EPHX1EPHX2RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932338-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-04-03 | — | — | US | disclosed |
| US-20170158694-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-08 | — | — | US | disclosed |
| WO-2017093208-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158694-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | EPHX1 1279/4885EPHX2 793/4885RAB9A 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.